Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics Corp. (DOSE.CN) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Rapid Dose Therapeutics Corp. (DOSE.CN), featuring income statements, balance sheets, and cash flow data.
Rapid Dose Therapeutics Corp. (DOSE.CN) Income Statement & Financial Overview
Explore comprehensive income reports for Rapid Dose Therapeutics Corp. DOSE.CN, broken down by year and quarter.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $668577.00 | $501689.00 | $515916.00 | $398994.00 |
| Cost of Revenue | $343552.00 | $231355.00 | $187920.00 | $1.009M |
| Gross Profit | $325025.00 | $270334.00 | $327996.00 | $256704.00 |
| Gross Profit Ratio | $0.49 | $0.54 | $0.64 | $0.64 |
| R&D Expenses | $48624.00 | $44086.00 | $26019.00 | $29516.00 |
| SG&A Expenses | $1.56M | $1.20M | $1.11M | $1.10M |
| Operating Expenses | $1.67M | $1.29M | $1.19M | $1.21M |
| Total Costs & Expenses | $2.01M | $1.52M | $1.37M | $1.35M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $338472.00 | $347755.00 | $242146.00 | $304033.00 |
| Depreciation & Amortization | $59646.00 | $48160.00 | $50215.00 | $82733.00 |
| EBITDA | -$1.28M | -$969000.00 | -$807000.00 | -$872000.00 |
| EBITDA Ratio | -$1.92 | -$1.93 | -$1.56 | -$2.19 |
| Operating Income | -$1.34M | -$1.02M | -$807298.00 | -$872000.00 |
| Operating Income Ratio | -$2.009 | -$2.03 | -$1.56 | -$2.19 |
| Other Income/Expenses (Net) | -$338472.00 | -$348000.00 | -$242000.00 | -$304000.00 |
| Income Before Tax | -$1.68M | -$1.36M | -$1.10M | -$1.26M |
| Income Before Tax Ratio | -$2.52 | -$2.72 | -$2.13 | -$3.15 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$3.00 |
| Net Income | -$1.68M | -$1.36M | -$1.10M | -$1.26M |
| Net Income Ratio | -$2.52 | -$2.72 | -$2.13 | -$3.15 |
| EPS | -$0.01 | -$0.01 | -$0.009 | -$0.01 |
| Diluted EPS | -$0.01 | -$0.01 | -$0.009 | -$0.01 |
| Weighted Avg Shares Outstanding | $129.53M | $124.17M | $123.12M | $121.76M |
| Weighted Avg Shares Outstanding (Diluted) | $129.53M | $124.17M | $123.12M | $121.76M |
Financial performance has remained strong, with revenue growing from $398994.00 in Q1 2024 to $668577.00 in Q4 2024. Gross profit continued to perform well, with margins at 49% in the latest quarter. Operating income reached -$1.34M in Q4 2024, holding a steady -201% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.28M. Net income dropped to -$1.68M, keeping EPS at -$0.01. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan